Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

ADXS-HPV receives orphan drug designation for HPV-associated anal cancer

Aug. 19, 2013

Phase II trial of Adcetris in combination with standard of care for frontline DLBCL commences

Aug. 19, 2013

Altor receives IND clearance to advance ALT-803 into clinical trials in melanoma

Aug. 16, 2013

Patrys discloses additional data from phase I/II trial of PAT-SM6 in MM

Aug. 16, 2013

Immunomedics advances solid tumor ADC programs to phase II

Aug. 13, 2013

Celldex Therapeutics expands phase II ReACT study in recurrent glioblastoma

Aug. 13, 2013

T-VEC shows potential as a treatment option for melanoma patients in phase III trials

Aug. 13, 2013

NWBio receives clearance in Germany to proceed with phase III DCVax-L trial

Aug. 12, 2013

GSK files MAA with EMA for use of Cervarix in two-dose schedule

Aug. 8, 2013

OncoTherapy's phase III trial of peptide cocktail vaccine for pancreatic cancer remains on schedule

Aug. 2, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...